Clinical Trials
21 trialsNCT06303193 2026-06-05
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT00534430 2026-06-03
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00544115 2026-06-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00843882 2026-05-29
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01522976 2026-05-29
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02727803 2026-05-22
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04902833 2026-05-19
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Massachusetts General Hospital
Completed
NCT03816319 2026-05-18
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
Phase 1 Suspended
NCT07588360 2026-05-14
Haplo-Cord HSCT for AML/MDS
Fujian Medical University Union Hospital
Phase NA Recruiting
NCT05320198 2026-05-13
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
Phase 1/2 Recruiting
NCT05600894 2026-05-13
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06499285 2026-05-13
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
NCT05350748 2026-05-08
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
National Institutes of Health Clinical Center (CC)
Recruiting
NCT05732961 2026-05-05
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04256317 2026-04-30
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
NCT06599762 2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2 Recruiting
NCT07532824 2026-04-16
UHKT-PTC-TMI-1
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 1/2 Recruiting
NCT03192397 2026-04-14
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT00392353 2026-04-13
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05972577 2026-04-06
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT05796570 2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2 Recruiting